Literature DB >> 19003124

A recombinant bait region mutant of human alpha2-macroglobulin exhibiting an altered proteinase-inhibiting spectrum.

A Ikai, K Ookata, M Shimizu, N Nakamichi, M Ito, T Matsumura.   

Abstract

Alpha 2-macroglobulin (alpha2M), a plasma glycoprotein produced in the liver, inhibits a variety of proteinases and thus considered to play important homeostatic roles in the body. This broad inhibitory spectrum has been explained by the trapping theory by which a proteinase recognizes a region of 25-30 amino acid peptide in alpha2M called bait region and cleaves it, leading to the conformational change of alpha2M, and to the subsequent entrapment and inhibition of the proteinase. We constructed alpha2M cDNAs with mutated DNA sequences in the bait region, and obtained recombinant CHO cell lines producing either wild type alpha2M, or mutant alpha2Ms, i.e., alpha2M/K692 and alpha2M/K696, each with substitution of Arg with Lys at codons 692 and 696, respectively. We tested if lysyl endopeptidase is not inhibited by wild type alpha2M, but could be inhibited by these engineered mutant alpha2Ms. Thus, recombinant alpha2M/K696 protein successfully inhibited lysyl endopeptidase activity, while recombinant alpha2M/K692 protein was not sensitive to lysyl endopeptidase, suggesting that not all bait region peptide bonds can equally be accessible and susceptible to proteinases. The present results not only provided the trapping theory with additional supportive evidence, but the first experimental evidence for the value of engineered alpha2M-derived proteinase inhibitor with an artificial proteinase inhibitory spectrum of potential industrial and/or therapeutic usefulness.

Entities:  

Year:  1999        PMID: 19003124      PMCID: PMC3449781          DOI: 10.1023/A:1008011919876

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  34 in total

1.  A 41.7 kDa serine protease from Clostridium perfringens type A: degradation of purified human serum proteins.

Authors:  U Wolf; D Bauer; W H Traub
Journal:  Zentralbl Bakteriol       Date:  1992-07

2.  Metalloproteases of Serratia liquefaciens: degradation of purified human serum proteins.

Authors:  U Wolf; D Bauer; W H Traub
Journal:  Zentralbl Bakteriol       Date:  1991-12

3.  Open quaternary structure of the hagfish proteinase inhibitor with similar properties to human alpha-2-macroglobulin.

Authors:  T Osada; M Nishigai; A Ikai
Journal:  J Ultrastruct Mol Struct Res       Date:  1986 Jul-Sep

4.  Novel complex formed between a nonproteolytic cell wall protein of group A streptococci and alpha 2-macroglobulin.

Authors:  G S Chhatwal; G Albohn; H Blobel
Journal:  J Bacteriol       Date:  1987-08       Impact factor: 3.490

5.  Dideoxy sequencing method using denatured plasmid templates.

Authors:  M Hattori; Y Sakaki
Journal:  Anal Biochem       Date:  1986-02-01       Impact factor: 3.365

6.  Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen.

Authors:  A Noda; Y Ning; S F Venable; O M Pereira-Smith; J R Smith
Journal:  Exp Cell Res       Date:  1994-03       Impact factor: 3.905

7.  Non-productive activation of the proteinase binding sites of alpha 2-macroglobulin on reaction of the inhibitor with matrix-linked trypsin.

Authors:  I Björk
Journal:  Biochem Biophys Res Commun       Date:  1984-01-30       Impact factor: 3.575

8.  Alpha 2-macroglobulin is the major neutralizing inhibitor of influenza A virus in pig serum.

Authors:  K A Ryan-Poirier; Y Kawaoka
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

9.  Different binding kinetics of Serratia 56K protease with plasma alpha 2-macroglobulin and chicken egg white ovomacroglobulin.

Authors:  A Molla; T Oda; H Maeda
Journal:  J Biochem       Date:  1987-01       Impact factor: 3.387

10.  alpha 2 Macroglobulin binding to the plasma membrane of cultured fibroblasts. Diffuse binding followed by clustering in coated regions.

Authors:  M C Willingham; F R Maxfield; I H Pastan
Journal:  J Cell Biol       Date:  1979-09       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.